What question did this study set out to answer?

The aim was to assess the safety and efficacy of CART19/20 cells in relapsed or refractory non-Hodgkin lymphoma.

Abstract LB-C001: Phase 1 Trial of Bispecific CART19/20 Cells for Relapsed or Refractory Non-Hodgkin Lymphoma: Updated Results with Over Four Years Median Follow Up

View Full Paper

Ask AI

Bookmark

The aim was to assess the safety and efficacy of CART19/20 cells in relapsed or refractory non-Hodgkin lymphoma.
Conducted a Phase 1 clinical trial with eligible patients aged 18+ and relapsed/refractory non-Hodgkin lymphoma.
Utilized autologous CD62L+ T cells modified with a bispecific anti-CD19/CD20 CAR through lentiviral transduction.
Assessed safety as the primary endpoint and clinical response, progression-free survival, and overall survival as secondary endpoints.
Fifteen patients received CART19/20, with a 93% overall response rate and an 80% complete response rate.
Median progression-free survival was 37.5 months with a mean peak cell expansion of 592,500 cells/mL.
Maximum cytokine release syndrome was grade 2 in one patient, along with 12 serious adverse events but no neurotoxicity.

No takes yet. Share an insight, caveat, or question.

Phase 1 trial evaluates CART19/20 cell therapy in relapsed/refractory non-Hodgkin lymphoma, suggesting effectiveness and safety.

Carlson et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark